Stock Market Reviews

Read and share opinions on MBRX (Moleculin Biotech, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
  Nov 13, 2025
• Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill
  Nov 12, 2025
• Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting
  Oct 30, 2025
• Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
  Oct 29, 2025
• Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
  Oct 23, 2025
• Moleculin Biotech announces issuance of Canadian patent covering Annamycin
  Sep 26, 2025
• Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin
  Sep 25, 2025
• Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know
  Sep 17, 2025
• Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
  Sep 9, 2025
• Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
  Sep 8, 2025
• Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds
  Aug 28, 2025
• Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
  Aug 14, 2025
• Moleculin Reports Second Quarter 2025 Financial Results and Highlights
  Aug 13, 2025
• Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment
  Aug 6, 2025
• Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin
  Jul 30, 2025
• Moleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
  Jul 22, 2025